Gamma Globulin Combined with Acyclovir for Children with Infectious Mononucleosis and Their Effect on Immune Function

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2023 Jul 12

PMID 37434807

Authors

Yuanyuan Li

Biquan Chen

Affiliations

Soon will be listed here.

Abstract

Background: Infectious mononucleosis (IM) is characterized by pharyngitis, cervical lymphadenopathy, fatigue and fever. IM is most commonly seen in primary Epstein-Barr virus (EBV) infection, with higher occurrence in children.

Objective: To explore the value of gamma globulin combined with acyclovir for IM children and their impact on immune function.

Methods: This prospective randomized controlled study recruited 111 children under 14 years old with IM from Anhui Provincial Children's Hospital during March 2019 and March 2022. Among them, 11 children dropped out, and 100 eligible children were randomized 1:1 into a control group and a study group. The control group received acyclovir, and the study group received additional gamma globulin. The baseline data, clinical efficacy, immune function, and adverse reactions were collected and compared.

Results: The study group had a shorter antipyretic time, lymph node reduction time, pharyngitis improvement time, and hospital stay compared to the control group (P < 0.05). The study group yielded lower levels of total white blood cell count, alanine aminotransferase, and creatine kinase-MB than the control group (P < 0.05). After treatment, the levels of CD3+ and CD8+ were lower, and the levels of CD4+, CD4+/CD8+, IgA, and IgG were higher in the study group than those in the control group (all P < 0.05). The incidence of adverse reactions between the two groups was comparable (14.00% vs. 24.00%). The positive rates of EBV-specific antibody and nuclear antigen in the study group were lower than those in the control group (P < 0.05).

Conclusion: The combined treatment of gamma globulin and acyclovir is a promising alternative for patients with IM compared to acyclovir alone. This combined regimen shortens the duration of clinical manifestations in children, promotes the recovery of laboratory indices, improves clinical efficacy, and enhances immune function. Furthermore, its safety profile is acceptable, warranting its further promotion.

References

Abrahamovych U, Abrahamovych O, Guta S, Tsyhanyk L, Romaniuk O . THE PECULIARITIES OF AVERAGE VALUES OF THE INDICES OF NON-VIRUS LABORATORY MARKERS OF ACTIVE EPSTEIN-BARR VIRUS INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Georgian Med News. 2020; (301):126-130. View

Fugl A, Andersen C . Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract. 2019; 20(1):62. PMC: 6518816. DOI: 10.1186/s12875-019-0954-3. View

Wei A, Li Z, Ma H, Zhang L, Zhang J, He L . Clinical Analysis of Chronic Active Epstein-Barr Virus Infection Involving the Gastrointestinal Tract. Pediatr Infect Dis J. 2022; 42(1):13-19. DOI: 10.1097/INF.0000000000003734. View

Womack J, Jimenez M . Common questions about infectious mononucleosis. Am Fam Physician. 2015; 91(6):372-6. View

Cauldwell K, Williams R . Unusual presentation of Epstein-Barr virus hepatitis treated successfully with valganciclovir. J Med Virol. 2013; 86(3):484-6. DOI: 10.1002/jmv.23766. View

Niazi B, Ali S, Elias S, Sciarra M . Protein Loss Enteropathy as an Initial Presentation of Gastric Epstein-Barr Virus Lymphoma. Case Rep Gastrointest Med. 2022; 2022:5143760. PMC: 9205741. DOI: 10.1155/2022/5143760. View

Lion T . Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014; 27(3):441-62. PMC: 4135893. DOI: 10.1128/CMR.00116-13. View

De Paor M, OBrien K, Fahey T, Smith S . Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016; 12:CD011487. PMC: 6463965. DOI: 10.1002/14651858.CD011487.pub2. View

Sakamoto Y, Mariya Y, Kubo K . Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection. Tohoku J Exp Med. 2012; 227(4):307-11. DOI: 10.1620/tjem.227.307. View

10.

Lu B, Kojima L, Huang M, Friedmann A, Ferry J, Weinstein H . Facial manifestations of Epstein-Barr virus-related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: Two atypical presentations. Pediatr Blood Cancer. 2016; 63(11):2042-5. DOI: 10.1002/pbc.26102. View

11.

Shi T, Huang L, Luo L, Yu Q, Tian J . Diagnostic value of serological and molecular biological tests for infectious mononucleosis by EBV in different age stages and course of the disease. J Med Virol. 2020; 93(6):3824-3834. DOI: 10.1002/jmv.26558. View

12.

Hu H, Deng H, Bi J, Xu Y, Li S, Xie Y . Clinical characteristics and effectiveness of antiviral agents in hospitalized children with infectious mononucleosis in China: A multicenter retrospective study. Pediatr Investig. 2021; 5(3):188-194. PMC: 8458718. DOI: 10.1002/ped4.12294. View

13.

Styczynski J, van der Velden W, Fox C, Engelhard D, de la Camara R, Cordonnier C . Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7):803-11. PMC: 5004459. DOI: 10.3324/haematol.2016.144428. View

14.

Ouedraogo D, Makinson A, Vendrell J, Casanova M, Nagot N, Cezar R . Pivotal role of HIV and EBV replication in the long-term persistence of monoclonal gammopathy in patients on antiretroviral therapy. Blood. 2013; 122(17):3030-3. DOI: 10.1182/blood-2012-12-470393. View

15.

Wang Q, Wang Z, Cao M, Wang Z . [Changes of FoxP3, CD4(+)CD25(+) regulatory T cells, TLR2 and TLR9 in children with infectious mononucleosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013; 21(2):469-73. DOI: 10.7534/j.issn.1009-2137.2013.02.044. View

16.

Gao L, Xie Z, Liu Y, Wang Y, Shen K . Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China. World J Pediatr. 2010; 7(1):45-9. DOI: 10.1007/s12519-011-0244-1. View

17.

Ebell M, Call M, Shinholser J, Gardner J . Does This Patient Have Infectious Mononucleosis?: The Rational Clinical Examination Systematic Review. JAMA. 2016; 315(14):1502-9. DOI: 10.1001/jama.2016.2111. View

18.

Bollard C, Cohen J . How I treat T-cell chronic active Epstein-Barr virus disease. Blood. 2018; 131(26):2899-2905. PMC: 6024635. DOI: 10.1182/blood-2018-03-785931. View

19.

Sulik A, Oldak E, Kroten A, Lipska A, Radziwon P . Epstein-Barr virus effect on frequency of functionally distinct T cell subsets in children with infectious mononucleosis. Adv Med Sci. 2014; 59(2):227-31. DOI: 10.1016/j.advms.2014.04.003. View

20.

Middeldorp J . Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. Curr Top Microbiol Immunol. 2015; 391:289-323. DOI: 10.1007/978-3-319-22834-1_10. View